Myelofibrosis Guideline Updates 2024 | videos

Aaron Gerds, MD, MS, explores the future landscape of myelofibrosis with insights from the 2003 ASH Annual Meeting and Exposition (ASH 2023), and delves into anticipated data on combination therapies and ongoing trials shaping the next phase of myelofibrosis treatment.

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guidelines for monitoring myelofibrosis treatment response and delves into crucial aspects like patient impressions, physical examinations, and symptoms.

Aaron Gerds, MD, MS, explores the FDA approval of momelotinib and its swift integration into National Comprehensive Cancer Network (NCCN) guidelines. He reviews different JAK inhibitors based on adverse effects and treatment goals, addressing potential treatment-related anemia in myelofibrosis.

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guideline categories, including evidence, and recommendations for symptomatic high-risk myelofibrosis. He discusses considerations for selecting JAK inhibitors and the threshold for switching treatments based on responses.

Aaron Gerds, MD, MS, discusses key updates in the National Comprehensive Cancer Network (NCCN) guidelines for myelofibrosis, including new treatments such as momelotinib and refined recommendations for different patient populations. He reviews symptom management, spleen size, and supportive care measures for optimal patient outcomes.

Aaron Gerds, MD, MS, explores myelofibrosis risk assessment, treatment goals, and therapeutic strategies, including JAK (Janus kinase inhibitors) inhibitors and transplant considerations.

Aaron Gerds, MD, MS, compares myelofibrosis with other myeloproliferative neoplasms, explores its prevalence in the US, and reviews the diverse clinical presentations and the impact on patients’ quality of life.

Aaron Gerds, MD, MS, reviews myeloid disorder myelofibrosis and presents diverse symptoms, from blood count variations to spleen enlargement.